Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
We report on the outcomes of 53 patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia secondary to MDS, autografted in first complete remission. Five (9.4%) died from the procedure whereas hematological reconstitution occurred in all the remaining patients. Forty patients (75%) relapsed, with 87.5% of the relapses occurring within 2 years of the autologous transplant. With a median follow-up of 6.2 years, the median actuarial disease-free survival and overall survival were 8 and 17 months after autograft, respectively. Karyotype was the only prognostic factor for disease-free and overall survival. The eight survivors (15%), including two patients with unfavorable or intermediate karyotype, remained in first complete remission 50+ to 119+ months after transplantation and are probably cured.
Ducastelle
Sophie
S
Service d'Hématologie, Pavillon E, CHU, Hôpital Edouard Herriot, 5, place d'Arsonval, 69437 Lyon Cédex 03, France.
Adès
Lionel
L
Gardin
Claude
C
Dombret
Hervé
H
Prébet
Thomas
T
Deconinck
Eric
E
Rio
Bernard
B
Thomas
Xavier
X
Debotton
Stephan
S
Guerci
Agnès
A
Gratecos
Nicole
N
Stamatoullas
Aspasia
A
Fegueux
Nathalie
N
Dreyfus
François
F
Fenaux
Pierre
P
Wattel
Eric
E
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D033581:Stem Cell Transplantation; D015996:Survival Rate; D013995:Time; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
D000970:Antineoplastic Agents